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ABSTRACT
Chromatin regulators (CRs) can dynamically mod-
ulate chromatin architecture to epigenetically regu-
late gene expression in response to intrinsic and ex-
trinsic signalling cues. Somatic alterations or mis-
expression of CRs might reprogram the epigenomic
landscape of chromatin, which in turn lead to a wide
range of common diseases, notably cancer. Here,
we present CR2Cancer, a comprehensive annota-
tion and visualization database for CRs in human
cancer constructed by high throughput data anal-
ysis and literature mining. We collected and inte-
grated genomic, transcriptomic, proteomic, clinical
and functional information for over 400 CRs across
multiple cancer types. We also built diverse types of
CR-associated relations, including cancer type de-
pendent (CR-target and miRNA-CR) and independent
(protein-protein interaction and drug-target) ones.
Furthermore, we manually curated around 6000 items
of aberrant molecular alterations and interactions of
CRs in cancer development from 5007 publications.
CR2Cancer provides a user-friendly web interface to
conveniently browse, search and download data of
interest. We believe that this database would become
a valuable resource for cancer epigenetics investiga-
tion and potential clinical application. CR2Cancer is
freely available at http://cis.hku.hk/CR2Cancer.
INTRODUCTION
Chromatin biology has been the focus of intense research
due to its significant implication in development and patho-
genesis (1). Chromatin is a macromolecular complex of
DNAand histone proteins forming repeating units of nucle-
osome, which consists of 147 bp of DNA wrapped around
an octamer of histones (two copies of H2A, H2B, H3 and
H4) (2). The interplay of epigenetic mechanisms regulates
the architecture of chromatin to control DNA-templated
processes such as transcription, replication and repair (3,4).
These epigenetic marks mainly include DNA methylation,
covalent histone modifications (e.g. acetylation and methy-
lation) and nucleosome placement, which constitute a dy-
namically changing and complex epigenomic landscape.
Chromatin regulators (CRs), a class of enzymes with spe-
cialized function domains, can recognize, shape and main-
tain the epigenetic state in a cell context-dependent fashion
(5). For instance, DNAmethyltransferases (DNMTs) trans-
fer methy groups to 5′ position of cytosines in CpG dinu-
cleotides while ten-eleven translocation (TET) enzymes cat-
alyze demethylation (6). Histone acetyltransferases (HATs)
and deacetylases (HDACs) can deposit and remove acetyl
groups to lysine amino acids on histone N-terminal tails,
respectively (7). Chromatin remodeling complexes are capa-
ble of either moving, evicting or restructuring nucleosomes
in an ATP-dependent manner (8).
Genomic alterations or dysregulation of CRs have now
been identified in a wide range of cancer types and are
increasingly regarded as novel therapeutic targets (9–11).
Since CRs can regulate local or global epigenetic patterns
to influence multiple target genes simultaneously, aberrant
CRs offer cancer cells a highly efficientmechanism to rewire
transcriptional regulatory circuits. Recent cancer genome
sequencing studies showed that CR genes are among the
most recurrently mutated gene sets (e.g. DNMT3A, EP300,
CREBBP, ARID1A and SMARCB1), and 25%-30% of the
identified driver mutations have an effect on genes encod-
ing CRs (12,13). For example, the histone methyltrans-
ferase EZH2 is mutated in 22% of diffuse large B cell lym-
phoma cases, which directly promotes the trimethylation
of histone H3 at K27 mark (H3K27me3) to repress the
expression of genes required for cell cycle exit and cell
differentiation (14,15). In addition, the reversible nature
of epigenetic modifications provides plausible prevention
and treatment options for cancer therapy through target-
ing CRs (16,17). As the first epigenetic therapies approved
in 2005, two DNMT1 inhibitors (5-azacytidine and 5-aza-
2′-deoxycytidine) can induce global hypomethylation for
the treatment of myelodysplastic syndrome (18,19). Sub-
sequently, more than 6 molecules inhibiting the activity
of HDACs have also been granted for clinical use in sev-
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eral cancers (20). Apart from these approved drugs, a large
number of novel molecules targeting various CRs, such as
EZH2, EP300, SIRT1 and LSD1, are currently under devel-
opment or in clinical trials, which provide an exciting out-
look for cancer epigenetic therapies (16,17).
It is therefore clear that comprehensive collection of CRs
together with related annotation information would con-
tribute greatly to the study of cancer development and treat-
ment. Currently, there are three major databases developed
for CRs and histone modifications. HIstone collects 55 hi-
stone proteins, 106 distinct sites of their modifications and
152 histone-modifying enzymes in human (21). WERAM
stores experimentally identified and computationally pre-
dicted histone regulators as well as site-specific regulator-
histone relations in eukaryotes (22). CRCistrome integrates
ChIP-Seq data of CRs and histone modifications to specif-
ically explore their relationships in human and mouse (23).
These data resources mainly focus on the collection of ba-
sic information and ChIP-Seq data of CRs, and include less
knowledge about DNAmethylation and chromatin remod-
eling proteins. Although they are crucial for deciphering the
mechanism and function of CRs, a systematic and special-
ized source for CRs in human cancer is needed urgently.
Over the past decade, large-scale cancer genomic projects,
such as The Cancer Genome Atlas (TCGA) (24) and the
Cancer Cell Line Encyclopedia (CCLE) (25), have pro-
duced multi-dimensional omics data for a number of can-
cer types. This definitely provides biologists an opportu-
nity to uncover the molecular mechanisms of regulation
and interaction in pan-cancer level (26–28). In addition,
low-throughput experiments of tumor-associated CRs are
rapidly emerging, but hidden in thousands of scattered
publications. In this study, we curated, assembled and in-
tegrated these data as well as other public resources to
build a database CR2Cancer with user-friendly interface
for easy data access. Through this database, users can ex-
plore the functional, genomic, transcriptomic, proteomic,
clinical, biological network and literature-reported infor-
mation for CRs across multiple cancer types. We believe
that CR2Cancer represents a valuable resource that pro-
vides unique and useful knowledge of CRs for investigators
in cancer epigenetics research community.
DATABASE OVERVIEW
CR2Cancer contains over 400 CRs that are annotated with
eleven categories of knowledge (Figure 1). (i) The function
category provides information on protein domains, func-
tion description and classification as well as substrates and
products of chemical reactions that CRs catalyze. In ad-
dition, this category shows the Gene Ontology terms and
pathways includingKEGG (29) andReactome (30). (ii) The
mutation category offers mutation landscape of primary tu-
mor tissues and cancer cell lines in single and pan-cancer
level. For each primary tumor type, effect of semantic mu-
tation on protein activity is examined and presented in this
category. In addition, we also collected various kinds of
mutations from COSMIC (31), and curated mutated CRs
from publications. (iii) The post-translational modification
(PTM) category allows users to scan the positions, modi-
fications and upstream enzymes of PTMs extracted from
Figure 1. Overview of CR2Cancer. CR2Cancer is composed of eleven cat-
egorized annotations for 429 CRs in cancer by high throughput data anal-
ysis and literature mining.
UniProt, and explore whether PTMs are affected by muta-
tions. (iv) The RNA expression category shows expression
pattern in primary tumor tissues, cancer cell lines, and hu-
man normal tissues. For primary tumor types with>10 cor-
responding normal samples, the results of differential ex-
pression analysis are also shown here. Moreover, this cat-
egory includes dysregulated patterns of CRs in cancer re-
trieved by literature mining. (v) The copy number category
offers correlation analysis between RNA expression and se-
mantic copy number alteration (SCNA) across various can-
cer types. In addition, users can examine the percentage of
samples for three classes of copy number change, i.e., gain,
loss and neutral. (vi) Similar to copy number category, the
methylation category offers correlation analysis between
RNA expression and promoter methylation level as well as
differential methylation status between tumor and normal
samples. (vii) The proteomics category is based on reverse
phase protein array (RPPA) data for primary tumor tissues
and antibody staining level for human normal tissues. (viii)
The clinical category shows association tests between RNA
expression and clinical features, including subtype, overall
survival, stage and grade. (ix) The target category presents
transcriptional targets of CRs inferred by reverse engineer-
ing method and ChIP-Seq data analysis. (x) The drug cat-
egory offers drug- and gene-centric networks derived from
DrugBank (32) to highlight the druggable nature of CRs.
(xi) The interaction category includes three parts: protein-
protein interaction (PPI) network with co-occurrence and
mutual exclusive mutation analysis, miRNA-target regula-
tory connections with expression correlation, and multiple
types of interactions reported in literatures.
DATABASE CONSTRUCTION
Data collection
A comprehensive list of 429 CRs functioning as DNAmod-
ifiers, histone-modifying enzymes or chromatin remodel-
ers, was compiled from three recent papers (33–35). Among
them, 167 (38.9%) CRs have been gathered in three can-
cer gene databases, i.e. 50 in ONGene (36), 72 in TSGene
(37) and 100 in NCG (38). We annotated all CRs with full
name, aliases, chromosome location and external IDs. In
addition, the site-specific substrates and products of CRs
were acquired from EpiFactors (39). The somatic muta-
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tion, RNA-Seq, DNA copy number, methylation, RPPA
and clinical data of primary tumor tissues were downloaded
from TCGA; the mutation profiles and gene expression mi-
croarray data of cancer cell lines fromCCLE; the RNA-Seq
and antibody staining data of human normal tissues from
The Human Protein Atlas (HPA) (40).
Literature mining
A text mining pipeline was developed to extract cancer-
associated CRs from public peer review papers. First, we
used ‘cancer’, ‘tumor’ and ‘carcinoma’ as keywords to
search PubMed database and downloaded all retrieved ab-
stracts (update to 1 August 2017). Second, these abstracts
were split into single sentences using GENIA Sentence
Splitter for the input of next step (41). Third, we located
gene names in the sentences by using BANNER (42) and
normalized the identified gene names based on a dictionary
comprised of official names and aliases of CRs. Finally, the
CR-mentioned sentences were manually curated to extract
aberrant molecular changes (e.g. mutation and dysregula-
tion) of CRs and their interactions with other biological
molecules in specific cancer type. The cancer names in our
results were normalized to the ‘Preferred Name’ registered
in NCI Thesaurus. In current release, CR2Cancer recruits
around 4700 aberrant molecular changes and 1300 interac-
tions for 358 CRs from 5007 publications.
Mutation landscape creation
We collected semantic mutation data of 8,788 primary tu-
mor samples in 26 cancer types and 967 cancer cell lines in
24 cancer types. Lollipop mutation diagrams of single nu-
cleotide variation (SNV, e.g. missense, nonsense and silent)
were produced in single and pan-cancer level using Lol-
lipops software (43). The mutational distribution of CRs
across cancer types were calculated and visualized in pie
charts for primary tumor tissues and cancer cell lines, re-
spectively. Moreover, we also retrieved over 120 000 seman-
ticmutations for 412CRgenes fromCOSMICv81 data sets.
RNA expression data preparation
For RNA-Seq data of primary cancer types, we normalized
raw counts matrix using Voom (44) after filtering out genes
that have over one count per million mapped reads in less
than 5% samples. Differential expression analysis was car-
ried out by using limma package (45) for 15 cancer types
with >10 corresponding normal samples (Fold Change >
1.5 and adjusted P-value < 0.05). In addition, the expres-
sion level of CRswas visualized across diverse cancer/tissue
types, and a total of 1228 images about gene expressionwere
included in the CR2Cancer database.
Correlation between RNA expression and copy number,
methylation or clinical features
In each cohort, the percentage of patients with copy number
loss, neutral and gain is subject to –1/2, 0 and +1/2 copy
number threshold based on GISTIC output (46). Pearson
correlations were used to assess relationships betweenRNA
expression and copy number value. Themethylation level of
CRs was represented by the probe in the promoter region
with themost negative correlationwith expression, and Stu-
dent’s t-test was used to examine the differential methyla-
tion status between tumor and normal samples. In addition,
Spearman correlations were used to assess relationships be-
tween expression and methylation, stage or grade. The log-
rank test was used to examine whether RNA expression sig-
nificantly correlated with the overall patient survival times.
Kruskal-Wallis test was used to determine if there are sig-
nificant differences among multiple tumor subtypes on ex-
pression.
Identification of transcriptional targets
We identified transcriptional targets of CRs based on two
strategies, i.e., reverse engineering and ChIP-Seq data anal-
ysis. Using gene expression profiles in cancer, ARACNe (47)
was runwith default parameters to prioritize cancer-specific
CR-target relations based on mutual information and data
processing inequality, which can reduce the number of in-
direct connections. In addition, there now exist several re-
sources for high quality processed ChIP-Seq data of hu-
man cell lines and tissues (23,48,49). CistromeDB is by far
the most comprehensive one for ChIP-Seq and chromatin
accessibility data analyzed through the standard analysis
pipeline (49). We downloaded 1359 ChIP-Seq BED files of
139 CRs from CistromeDB, and used BETA (50) to infer
the putative target genes.
Effect of semantic mutations on protein activity
The protein activity of CRs was calculated by using VIPER
(51) from gene expression profile data and ARACNe-
inferred targets. Considering those CRs with at least 20
nonsilent mutated samples in single cancer type (291 pairs,
e.g. ARID1A in gastric cancer), we compared the protein
activity between samples with and without mutations to
evaluate the functional effect of mutations (Wilcoxon test).
Interaction network
Around 280,000 protein-protein interactions involved in
CRs and their first neighbours were extracted from Path-
way Commons v8 (52). In addition, we carried out co-
occurrence andmutual exclusivemutation analysis (Fisher’s
exact test) for each edge based on cancer genome sequenc-
ing data. The miRNA-CR regulatory relations were in-
tegrated from several experiment validation or sequence-
based prediction databases such asRAID (53), mir2Disease
(54),miRTarBase (55),miRDB (56),miRWalk (57) andTar-
getSCAN (58). We then calculated Pearson correlations be-
tween the expression levels of miRNA and CR, and sorted
the 12,000 miRNA-CR pairs by the frequency of cancer
types in which they are negatively correlated (P-value <
0.05).
USER INTERFACE
CR2Cancer provides a friendly interface for users to
browse, search and download data. In the ‘Browse’ page,
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Figure 2. Browse page for ARID1A in CR2Cancer. A user can access different categorized annotations by clicking the tabs at the top of the page.
the user can browse CRs by six different panels: ‘Cancer
Type’, ‘Function’, ‘Mutation Rate’, ‘Differential Expres-
sion’, ‘ChIP-Seq Data’ and ‘Targeted Drug’. The ‘Cancer
Type’ shows 26 and 24 cancer types from primary tumor tis-
sues and cancer cell lines, respectively. By clicking one can-
cer type, a summary table of all CRs in this cancer can be
presented. The ‘Function’ panel offers detailed function an-
notations of CRs, and users can click the buttons at the top
of the panel to filter them by DNA modification, histone
modification and chromatin remodelling. In the ‘Mutation
Rate’ page, users can obtain the mutation rate of CRs in
8,788 primary tumor samples and in 967 cancer cell lines.
We observed that five CRs, KMT2C, ARID1A, CREBBP,
TRRAP and TAF1L, are common in the top 10 mutated
CR genes of tumor tissues and cell lines. The ‘Differential
Expression’ page summaries differential expression analy-
sis of CRs in 15 primary cancer types with more than ten
normal samples. We found that 327 (76.2%) CRs are dif-
ferentially expressed in at least one cancer type, and most
of them show consistent (up- or down-) dysregulated pat-
terns across diverse cancers. Finally, users can browse 139
CRs with ChIP-Seq profiles and 39 CRs regarded as drug
targets in ‘ChIP-Seq Data’ and ‘Targeted Drug’ panels, re-
spectively. In above pages, to click on the hyperlinks of gene
symbols can pinpoint to the entry page of CR, which in-
cludes 11 categories of knowledge in different tabs (Figure
2). For each tab, the summary table contains basic informa-
tion of CR and relevant contents in this tab, which is linked
to responding parts for more details. In the ‘Search’ page,
CR2Cancer can be queried in an easy-to-use manner with
a number of search tools. Users can retrieve CRs of inter-
est in simple and batch format by gene symbol, name, En-
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trez ID, UniProt ID, ensembl ID and substrates. Moreover,
users can search cancer name of primary tumors, cell lines
and text mining results, and obtain a summary page of CRs
involved in this cancer. The ‘Advanced search’ module al-
lows users to query gene and cancer at the same time, and
returns the related information of queried CR in the tumor
type of interest. In order to conduct advanced data analy-
sis, we have prepared all data in plain text files, which can
be accessed from the ‘Download’ page.
DISSCUSSION AND FUTURE DIRECTIONS
Cancer is a large group of more than 200 diseases char-
acterized by uncontrolled cell growth. Although it is typi-
cally viewed as a genetic disorder, increasing evidences show
that the deregulation of epigenetic mechanisms represents a
common feature of tumorigenesis and metastasis (1). Com-
prehensive analyses of cancer genomes have also revealed
that CR genes involved in epigenetic modification are of-
ten mutated across diverse cancer types (12,13). These find-
ings firmly establish that epigenetic alterations are not just
a result of the cancerous state but play causal roles in dis-
ease pathogenesis. Furthermore, it is now clear that cross
talk between genetic and epigenetic mechanisms enable the
acquisition of cancer hallmarks (59). In addition, the re-
versible nature of epigenetic modifications makes CRs ap-
pealing drug targets for cancer therapy, and a number of
small molecules that inhibit the activity of aberrant CRs
have been in clinical use or trial (16,17). With the exponen-
tial growth of cancer biomedical data, a comprehensive re-
source for CRs in cancer has become especially imperative
for cancer epigenetics research.
In this study, we developed a database CR2Cancer that
collects annotation data and abnormal patterns of CRs in
human cancer based on high throughput data analysis and
literature mining. The information is integrated into 11 cat-
egories for each CR: function, mutation, PTM, RNA ex-
pression, copy number, methylation, proteomics, clinical,
target, drug and interaction. Users can browse all CRs by
six different paths or use the advanced search tools to ac-
cess the CR of interest. Compared with the previous similar
databases (21–23), CR2Cancer mainly has two distinctive
characteristics. On one hand, in addition to basic knowl-
edge of CRs, our database provides their multi-dimensional
molecular scheme (e.g. genome, transcriptome and pro-
teome) and integrative analyses (e.g. association tests be-
tween expression and copy number, methylation or clini-
cal features) across various human cancers. On the other
hand, CR2Cancer combines both high-throughput and lit-
erature supported experiment data, which enable users to
cross check the role of CRs during cancer development. We
expect that CR2Cancer can serve investigators focusing on
cancer epigenetics for not only the elucidation of underpin-
nings of pathogenesis but also the design of novel targeted
therapy.
In the future, we will collect more large-scale cancer ge-
nomics data sets from several separated studies (60) and
special consortiums (61), which can offer in-depth knowl-
edge of the commonalities and differences among different
cancer types or same ones in different platforms. We also
will continually curate the literatures on cancer-associated
CRs in a regular basis. Furthermore, genome-wide maps
of DNA methylation, histone modifications and chromatin
accessibility will be integrated in our database to provide
insights of gene regulation through complex processes that
involve functional elements, transcription factors and chro-
matin regulators (62). Finally, we plan to add drug pharma-
cological data from high throughput screening studies for
drug discovery and repurposing.
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